CL2019002624A1 - Compuestos y métodos para la reducción celular específica. - Google Patents

Compuestos y métodos para la reducción celular específica.

Info

Publication number
CL2019002624A1
CL2019002624A1 CL2019002624A CL2019002624A CL2019002624A1 CL 2019002624 A1 CL2019002624 A1 CL 2019002624A1 CL 2019002624 A CL2019002624 A CL 2019002624A CL 2019002624 A CL2019002624 A CL 2019002624A CL 2019002624 A1 CL2019002624 A1 CL 2019002624A1
Authority
CL
Chile
Prior art keywords
compounds
methods
specific cell
cell reduction
treat
Prior art date
Application number
CL2019002624A
Other languages
English (en)
Inventor
Sergio Quezada
Karl Peggs
Anne Goubier
Pascal Merchiers
Josephine Salimu
Corzo Beatriz Goyenechea
Kevin Moulder
Vargas Frederick Arce
Isabelle Solomon
Original Assignee
Cancer Research Tech Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd
Publication of CL2019002624A1 publication Critical patent/CL2019002624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE ENCUENTRA EN EL CAMPO DE LA INMUNOTERAPIA CONTRA EL CÁNCER Y SE REFIERE A UN MÉTODO PARA TRATAR EL CÁNCER, QUE INCLUYE UN MÉTODO PARA TRATAR TUMORES SÓLIDOS, EN DONDE EL MÉTODO IMPLICA EL USO DE UN ANTICUERPO ANTI-CD25 EN UN SUJETO QUE NO INHIBE SUSTANCIALMENTE LA UNIÓN DE INTERLEUCINA-2 (IL-2) EN CD25 O LA SEÑALIZACIÓN DE IL-2 A TRAVÉS DE CD25.
CL2019002624A 2017-03-17 2019-09-13 Compuestos y métodos para la reducción celular específica. CL2019002624A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion

Publications (1)

Publication Number Publication Date
CL2019002624A1 true CL2019002624A1 (es) 2020-04-03

Family

ID=61655786

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002624A CL2019002624A1 (es) 2017-03-17 2019-09-13 Compuestos y métodos para la reducción celular específica.

Country Status (19)

Country Link
US (1) US11879014B2 (es)
EP (1) EP3596123B1 (es)
JP (2) JP2020514363A (es)
KR (1) KR20190130137A (es)
CN (1) CN110869388A (es)
AU (1) AU2018233976A1 (es)
BR (1) BR112019017017A2 (es)
CA (1) CA3056506A1 (es)
CL (1) CL2019002624A1 (es)
CR (1) CR20190477A (es)
DK (1) DK3596123T3 (es)
FI (1) FI3596123T3 (es)
IL (1) IL269081A (es)
LT (1) LT3596123T (es)
MX (1) MX2019010974A (es)
PE (1) PE20191812A1 (es)
RS (1) RS65351B1 (es)
SG (1) SG11201908578YA (es)
WO (1) WO2018167104A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697688B2 (en) 2018-03-13 2023-07-11 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
JP2022507487A (ja) * 2018-11-14 2022-01-18 ルーブリック・セラピューティクス・インコーポレイテッド Ｃｄ２５抗体
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies
WO2020248938A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗cd25抗体及其应用
CN115942958A (zh) 2020-04-10 2023-04-07 乐天医药生技股份有限公司 酞菁染料化合物、缀合物及其使用方法
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
US20240002521A1 (en) * 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022106665A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
EP4288100A1 (en) * 2021-02-02 2023-12-13 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
WO2022184615A1 (en) 2021-03-01 2022-09-09 F. Hoffmann-La Roche Ag Novel biomarkers and uses thereof
TW202319400A (zh) 2021-09-02 2023-05-16 瑞士商赫孚孟拉羅股份公司 用於治療aml之抗體
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
WO2024006965A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ES2401136T3 (es) 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
KR20140033241A (ko) 2006-08-18 2014-03-17 노바르티스 아게 Ｐｒｌｒ 특이적 항체 및 그 용도
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2010054010A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
AU2011280893C1 (en) 2010-07-22 2016-02-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
MX2015012563A (es) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
WO2014145000A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3020204A1 (en) 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
RU2020128108A (ru) 2018-03-13 2022-04-13 Таск Терапьютикс Лтд Антитело против cd25 для опухоль-специфической клеточной деплеции

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697688B2 (en) 2018-03-13 2023-07-11 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11787866B2 (en) 2018-03-13 2023-10-17 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US11802161B2 (en) 2018-03-13 2023-10-31 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11802160B2 (en) 2018-03-13 2023-10-31 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US11814434B2 (en) 2018-03-13 2023-11-14 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11851494B2 (en) 2018-03-13 2023-12-26 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11873341B2 (en) 2018-03-13 2024-01-16 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11919960B2 (en) 2018-03-13 2024-03-05 Tusk Therapeutics Ltd. Anti-CD25 antibody agents

Also Published As

Publication number Publication date
MX2019010974A (es) 2020-08-03
WO2018167104A1 (en) 2018-09-20
CN110869388A (zh) 2020-03-06
EP3596123A1 (en) 2020-01-22
DK3596123T3 (da) 2024-02-26
US20200010554A1 (en) 2020-01-09
SG11201908578YA (en) 2019-10-30
CA3056506A1 (en) 2018-09-20
EP3596123B1 (en) 2024-01-10
CR20190477A (es) 2020-01-07
BR112019017017A2 (pt) 2020-04-14
RS65351B1 (sr) 2024-04-30
JP2024050684A (ja) 2024-04-10
KR20190130137A (ko) 2019-11-21
PE20191812A1 (es) 2019-12-26
AU2018233976A1 (en) 2019-10-31
US11879014B2 (en) 2024-01-23
IL269081A (en) 2019-11-28
JP2020514363A (ja) 2020-05-21
LT3596123T (lt) 2024-03-25
FI3596123T3 (fi) 2024-04-17

Similar Documents

Publication Publication Date Title
CL2019002624A1 (es) Compuestos y métodos para la reducción celular específica.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
MX2018010484A (es) Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
UY35961A (es) Anticuerpos y fragmentos anti-vista
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
NZ731467A (en) Anti-tim3 antibodies and methods of use
GT201600171A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda
EA201691916A1 (ru) Биарильные ингибиторы киназы
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
EA201991006A1 (ru) Полимерные системы для дисперсии частиц
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
ZA201804565B (en) Immunopotentiator enhanced superantigen mediated cancer immunotherapy
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
MX2020010657A (es) Derivados de oxadiazolina.
BR112019024719A2 (pt) Composições e métodos para resposta imunológica antitumor aprimorada
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1